Analyst Price Targets — ILMN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 3, 2026 11:06 am | — | Canaccord Genuity | $205.00 | $205.10 | TheFly | Illumina price target raised to $205 from $190 at Canaccord |
| July 31, 2026 2:09 pm | — | RBC Capital | $230.00 | $199.13 | TheFly | Illumina price target raised to $230 from $170 at RBC Capital |
| July 31, 2026 11:50 am | — | Bernstein | $215.00 | $205.09 | TheFly | Illumina price target raised to $215 from $185 at Bernstein |
| July 31, 2026 10:52 am | — | Guggenheim | $226.00 | $205.09 | TheFly | Illumina price target raised to $226 from $200 at Guggenheim |
| July 31, 2026 9:09 am | — | Barclays | $160.00 | $205.09 | TheFly | Illumina price target raised to $160 from $145 at Barclays |
| July 17, 2026 12:45 pm | Puneet Souda | Leerink Partners | $210.00 | $186.89 | TheFly | Illumina price target raised to $210 from $175 at Leerink |
| July 14, 2026 10:51 am | Kyle Mikson | Canaccord Genuity | $190.00 | $190.05 | TheFly | Illumina price target raised to $190 from $140 at Canaccord |
| June 29, 2026 11:00 am | — | Guggenheim | $200.00 | $176.55 | TheFly | Illumina price target raised to $200 from $180 at Guggenheim |
| June 26, 2026 10:27 am | — | Bernstein | $185.00 | $177.65 | TheFly | Illumina resumed with a Market Perform at Bernstein |
| June 1, 2026 11:27 am | — | Guggenheim | $180.00 | $162.96 | TheFly | Illumina price target raised to $180 from $170 at Guggenheim |
Latest News for ILMN
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Biondo Investment Advisors LLC bought a new stake in shares of Illumina, Inc. (NASDAQ: ILMN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,630 shares of the life sciences company's stock, valued at approximately $1,869,000. Several other institutional investors and
Allworth Financial LP acquired a new position in Illumina, Inc. (NASDAQ: ILMN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,976 shares of the life sciences company's stock, valued at approximately $1,051,000. Several other hedge funds and other institutional investors have
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.